Stay updated with breaking news from Davidr Spigel. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
CHICAGO — Osimertinib following chemoradiotherapy drastically improved PFS compared with placebo in patients with advanced EGFR-mutant non-small cell lung cancer in a randomized phase 3 trial.Blinded independent review and study investigators separately determined a greater than 80% risk reduction for those treated with the osimertinib-based regimen, according to results presented at ASCO
A pair of late-breaking trials, LAURA and ADRIATIC, promise practice-changing news in lung cancer.
Five-year follow-up data from the landmark CROWN trial shows significant progression-free survival in ALK+ NCSLC, but some experts question the use of crizotinib as the comparator drug.
CHICAGO — Lorlatinib delivered never-before-seen PFS results in adults with anaplastic lymphoma kinase-positive non-small cell lung cancer, according to findings from a randomized phase 3 trial presented at ASCO Annual Meeting.Lorlatinib (Lorbrena, Pfizer) also drastically delayed disease progression and development of brain metastases compared with crizotinib (Xalkori, Pfizer).
Phase 1 Trial of LYL797, a ROR1-Targeted CAR T-Cell Therapy Enhanced With Genetic and Epigenetic Reprogramming, in Advanced Triple-Negative...